Pavlo Kot

Eyepoint Pharmaceuticals sends team to New York to engage with industry leaders

Eyepoint Pharmaceuticals sends team to New York to engage with industry leaders
Eyepoint targets investor outreach

Eyepoint Pharmaceuticals is sending its team to New York City to participate in several investor conferences.

The company aims to connect with industry leaders and provide updates on its progress as part of its ongoing engagement with the investment community. These conferences present an opportunity for Eyepoint Pharmaceuticals to strengthen its industry relationships and potentially attract new partners or investors. Details on the specific conferences and company updates have not been disclosed. Details are being clarified.

Eyepoint Pharmaceuticals recently released topline results from its pivotal Phase 3 LUGANO trial of DURAVYU for wet AMD treatment, according to company disclosures. The company also reported promising outcomes for sustained release TKIs in wet AMD based on its Lugano trial results in a separate update earlier this year. These developments reflect ongoing activity as Eyepoint Pharmaceuticals engages with the investment community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.